Introduction

Increased airway resistance, a symptom of diseases such as asthma and chronic obstructive pulmonary disease (COPD), can be treated by drugs that relax airway smooth muscle (e.g., muscarinic antagonists or adrenergic agonists) by decreasing cytoplasmic Ca2+. Several ion channels that are key regulators of airway resistance and are implicated in various pulmonary and respiratory disorders: transient receptor potential (TRPA1, TRPC1, TRPC6, TRPV1, and TRPV4) are sensitive to various environmental stimuli and can modulate airway reactivity and vascular tone; chloride (CFTR) are involved in the transport of chloride ions, which can affect mucus clearance and airway hydration; ligand-gated (GABAA α5β2γ2): GABAA receptors, when activated, conduct chloride current and can lead to muscle relaxation; potassium, calcium-activated (BK and IK) when activated, could cause relaxation and bronchodilation; Kv1.5 is particularly important for vasodilation, which can alleviate pulmonary hypertension. purinergic receptors (P2X4): Involved in the regulation of smooth muscle tone and may play a role in bronchoconstriction; sodium, epithelial (ENaC): Regulates sodium transport across epithelial cells, which can influence airway surface liquid volume.

Pulmonary-Respiratory ion channel Portfolio

Our pulmonary-respiratory Ion Channel Portfolio is a curated collection of ion channels that play a significant role in pulmonary and respiratory function. This panel is designed to assess a compound's target specificity and potential off-target effects, which is crucial for the discovery of drugs that can effectively manage airway resistance and pulmonary hypertension. This panel is a valuable tool in the development of therapeutics for pulmonary and respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD).